2 years ago-Biopharma Group

Choice Matters: Diminishing Options as a Result of Industry Consolidation Place New Pressure on Customer Decision-making

Views: 357

Soaring merger & acquisition activity in life sciences threatens competition and reduces customer options, both to patients and to pharma and biotech firms seeking help with growing pharmacovigilance and regulatory filing requirements. Alan White of Arriello explains why it has never been more important to choose wisely.

Comments: 0

Your email address will not be published. Required fields are marked with *


Your Cart